Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call
Vivos Therapeutics (NASDAQ: VVOS), a medical device and technology company focused on sleep-related breathing disorders treatments, has scheduled its full year 2024 financial results release for Monday, March 31, 2025, after market close.
The company will host a conference call at 5:00 PM ET on the same day to discuss the results and provide updates on recent milestones. Investors can join via phone at (800) 717-1738 (US) or (646) 307-1865 (International). A replay will be available until April 14, 2025, using passcode 1103883. The webcast can be accessed through Vivos' investor relations website, with a 30-day archive available.
Vivos Therapeutics (NASDAQ: VVOS), un'azienda di dispositivi medici e tecnologia focalizzata sui trattamenti per i disturbi respiratori legati al sonno, ha programmato il rilascio dei risultati finanziari per l'intero anno 2024 per lunedì 31 marzo 2025, dopo la chiusura del mercato.
L'azienda ospiterà una conferenza telefonica alle 17:00 ET lo stesso giorno per discutere i risultati e fornire aggiornamenti sui recenti traguardi. Gli investitori possono partecipare telefonicamente al numero (800) 717-1738 (USA) o (646) 307-1865 (Internazionale). Una registrazione sarà disponibile fino al 14 aprile 2025, utilizzando il codice di accesso 1103883. Il webcast sarà accessibile tramite il sito web delle relazioni con gli investitori di Vivos, con un archivio disponibile per 30 giorni.
Vivos Therapeutics (NASDAQ: VVOS), una empresa de dispositivos médicos y tecnología enfocada en tratamientos para trastornos respiratorios relacionados con el sueño, ha programado la publicación de sus resultados financieros del año completo 2024 para el lunes 31 de marzo de 2025, después del cierre del mercado.
La empresa llevará a cabo una conferencia telefónica a las 5:00 PM ET el mismo día para discutir los resultados y proporcionar actualizaciones sobre logros recientes. Los inversores pueden unirse por teléfono al (800) 717-1738 (EE. UU.) o al (646) 307-1865 (Internacional). Una repetición estará disponible hasta el 14 de abril de 2025, utilizando el código de acceso 1103883. La transmisión web se podrá acceder a través del sitio web de relaciones con inversores de Vivos, con un archivo disponible durante 30 días.
비보스 테라퓨틱스 (NASDAQ: VVOS), 수면 관련 호흡 장애 치료에 중점을 둔 의료 기기 및 기술 회사는 2024년 전체 연도 재무 결과 발표를 2025년 3월 31일 월요일, 시장 마감 후로 예정했습니다.
회사는 같은 날 오후 5시 ET에 결과를 논의하고 최근 이정표에 대한 업데이트를 제공하기 위해 컨퍼런스 콜을 개최합니다. 투자자는 (800) 717-1738 (미국) 또는 (646) 307-1865 (국제)로 전화로 참여할 수 있습니다. 재생은 2025년 4월 14일까지 이용 가능하며, 비밀번호 1103883을 사용해야 합니다. 웹캐스트는 Vivos의 투자자 관계 웹사이트를 통해 접근할 수 있으며, 30일간의 아카이브가 제공됩니다.
Vivos Therapeutics (NASDAQ: VVOS), une entreprise de dispositifs médicaux et de technologies axée sur les traitements des troubles respiratoires liés au sommeil, a prévu la publication de ses résultats financiers pour l'année complète 2024 pour le lundi 31 mars 2025, après la clôture du marché.
L'entreprise organisera une conférence téléphonique à 17h00 ET le même jour pour discuter des résultats et fournir des mises à jour sur les jalons récents. Les investisseurs peuvent participer par téléphone au (800) 717-1738 (États-Unis) ou au (646) 307-1865 (International). Un enregistrement sera disponible jusqu'au 14 avril 2025, en utilisant le code d'accès 1103883. Le webinaire sera accessible via le site web des relations avec les investisseurs de Vivos, avec un archive de 30 jours disponible.
Vivos Therapeutics (NASDAQ: VVOS), ein Unternehmen für medizinische Geräte und Technologien, das sich auf die Behandlung von schlafbezogenen Atemstörungen konzentriert, hat die Veröffentlichung seiner finanziellen Ergebnisse für das gesamte Jahr 2024 für Montag, den 31. März 2025, nach Börsenschluss angesetzt.
Das Unternehmen wird am selben Tag um 17:00 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen und Updates zu aktuellen Meilensteinen zu geben. Investoren können telefonisch unter (800) 717-1738 (USA) oder (646) 307-1865 (international) teilnehmen. Eine Wiederholung wird bis zum 14. April 2025 verfügbar sein, mit dem Zugangscode 1103883. Der Webcast kann über die Investor-Relations-Website von Vivos aufgerufen werden, mit einem 30-tägigen Archiv.
- None.
- None.
Call Scheduled for Monday, March 31, 2025 at 5:00 pm ET
LITTLETON, Colo., March 28, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17), today announced it plans to release its full year 2024 financial results after market close on Monday, March 31, 2025. The Company will conduct a conference call at 5:00 p.m. (Eastern Time) on March 31, 2025 to review the results and provide an overview of the Company’s recent milestones and developments.
To access Vivos’ investor conference call, please dial (800) 717-1738, or for international callers, (646) 307-1865. A replay will be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The passcode for the replay is 1103883. The replay will be available until April 14, 2025.
A live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investor-relations. An online archive of the webcast will be available on the Company’s website for 30 days following the call.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17. The Vivos Method represents the first clinically effective nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating mild to severe OSA in adults and moderate to severe OSA in children ages 6-17. It has proven effective in approximately 58,000 patients treated worldwide by more than 2,000 trained dentists.
The Vivos Method includes treatment regimens that employ proprietary CARE appliance therapy and other modalities that alter the size, shape and position of the jaw and soft tissues that comprise a patient’s upper airway and/or palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-severe OSA in adults and moderate-to-severe OSA in children ages 6 to 17, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using The Vivos Method. Vivos also employs a marketing and distribution model where it collaborates with sleep-treatment providers to offer patients OSA treatment options and help promote sales of its appliances.
For more information, visit www.vivos.com.
Cautionary Note Regarding Forward-Looking Statements
This press release, the conference call referred to herein, and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including the actual future impact of the initiatives and corporate achievements described herein on Vivos’ future revenues and results of operations and the anticipated benefits of the Company’s new marketing and distribution model described herein) may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to implement revenue, sales and marketing strategies and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector; (iv) the risk that Vivos may be unable to secure additional financings on reasonable terms when needed, if at all, or maintain its Nasdaq listing (v) market and other conditions, and (vi) other risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.
Vivos Investor Relations and Media Contact:
Bradford Amman
Chief Financial Officer and Investor Relations Contact
investors@vivoslife.com
FAQ
When will Vivos Therapeutics (VVOS) release its 2024 annual financial results?
How can investors join the VVOS earnings conference call on March 31, 2025?
What is the replay passcode for VVOS's 2024 earnings call?
Where can investors access the webcast of VVOS's 2024 earnings call?
